Significant association between chronic antibody-mediated rejection and donor-specific antibodies against HLA-DRB rather than DQB in renal transplantation

Human Immunology

Volumn 72, Issue 1, 2011, Pages 11-17

  Kobayashi, Takaaki ^a   Maruya, Etsuko ^b   Niwa, Misao ^a   Saji, Hiroh ^b   Kohara, Setsuko ^c   Katayama, Akio ^d   Takeda, Asami ^c   Watarai, Yoshihiko ^c   Uchida, Kazuharu ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Japanese Red Cross Kanto Koshinetsu Block Blood Center   (Japan)

^c NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^d Masuko Memorial Hospital   (Japan)

Author keywords

Chronic antibody mediated rejection; Donor specific antibody; HLA antibody; HLA DRB; Renal transplantation

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQB1 ANTIGEN; HLA DR ANTIGEN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CHRONIC ANTIBODY MEDIATED REJECTION; CIRCULATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTIBODIES; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS; YOUNG ADULT;

EID: 78650176424     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.10.018     Document Type: Article

References (50)

1. Gebel H.M., Bray R.A. Sensitization and sensitivity: Defining the unsensitized patients. Transplantation 2000, 69:1370-1374.
2. Akalin E., Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 2006, 1:433-440.
3. Terasaki P.I., Cai J. Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation 2008, 86:377-383.
4. Lachmann N., Terasaki P.I., Budde K., Liefeldt L., Kahl A., Reinke P., et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009, 87:1505-1513.
5. Gill J.S., Landsberg D., Johnston O., Shapiro R.J., Magil A.B., Wu V., et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 2010, 89:178-184.
6. Böhmig G.A., Bartel G., Regele H., Wahrmann M. Prospects and limitations of post-transplantation alloantibody detection in renal transplantation. Hum Immunol 2009, 70:640-644.
7. Kobayashi T., Katayama A., Kohara S., Nagasaka T., Goto N., Ueki T., et al. Enzyme-linked immunosorbent assay for human leukocyte antigen antibody detection and urine protein test recommended for follow-up monitoring after renal transplantation. Transplantation 2008, 85:1595-1600.
8. Worthington J.E., Robson A.J., Sheldon S., Langton A., Martin S. A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol 2001, 62:1178-1184.
9. Monien S., Salama A., Schönemann C. ELISA methods detect HLA antibodies with variable sensitivity. Int J Immunogenet 2006, 33:163-166.
10. Ozawa M., Terasaki P.I., Lee J.H., Castro R., Alberu J., Alonso C., et al. 14th International HLA and Immunogenetics Workshop: Report on the Prospective Chronic Rejection Project. Tissue Antigens 2007, 69(Suppl 1):174-179.
11. Phelan D., Mohanakumar T., Ramachandran S., Jendrisak M.D. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009, 70:584-588.
12. Tait B.D. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009, 21:573-577.
13. Ponticelli C. Humoral antibodies in organ transplantation: Angels or demons?. Am J Transplant 2010, 10:1332.
14. Leffell M.S., Zachary A.A. Anti-allograft antibodies: Some are harmful, some can be overcome, and some may be beneficial. Discov Med 2010, 9:478-484.
15. Sis B., Mengel M., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., et al. Banff 2009 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010, 10:464-471.
16. Billen E.V., Christiaans M.H., Lee J., van den Berg-Loonen E.M. Donor-directed HLA antibodies before and after transplantectomy detected by the Luminex single antigen assay. Transplantation 2009, 87:563-569.
17. Marrari M., Duquesnoy R.J. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010, 22:105-109.
18. Loupy A., Suberbielle-Boissel C., Hill G.S., Lefaucheur C., Anglicheau D., Zuber J., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009, 9:2561-2570.
19. Lee P.C., Zhu L., Terasaki P.I., Everly M.J. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88:568-574.
20. Aubert V., Venetz J.P., Pantaleo G., Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009, 70:580-583.
21. Morris G.P., Phelan D.L., Jendrisak M.D., Mohanakumar T. Virtual crossmatch by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: A 30-month analysis in living donor kidney transplantation. Hum Immunol 2010, 71:268-273.
22. Leffell M.S., Zachary A.A. Antiallograft. Antibodies: Relevance, detection, and monitoring. Curr Opin Organ Transplant 2010, 15:2-7.
23. Mizutani K., Terasaki P., Hamdani E., Esquenazi V., Rosen A., Miller J., Ozawa M. The importance of anti-HLA-specific antibody strength in monitoring kidney transplant patients. Am J Transplant 2007, 7:1027-1031.
24. Reinsmoen N.L., Lai C.H., Vo A., Cao K., Ong G., Naim M., et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008, 86:820-825.
25. Gloor J.M., Winters J.L., Cornell L.D., Fix L.A., DeGoey S.R., Knauer R.M., et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010, 10:582-589.
26. Campos E.F., Tedesco-Silva H., Machado P.G., Franco M., Medina-Pestana J.O., Gerbase-DeLima M. Post-transplant anti-HLA class II antibodies as risk factor for late kidney allograft failure. Am J Transplant 2006, 6:2316-2320.
27. Langan L.L., Park L.P., Hughes T.L., Irish A., Luxton G., Witt C.S., Christiansen F.T. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007, 7:847-856.
28. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., et al. Transplant glomerulopathy: Risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008, 86:681-685.
29. Colvin R.B. Pathology of chronic humoral rejection. Contrib Nephrol 2009, 162:75-86.
30. Kreijveld E., Hilbrands L.B., van Berkel Y., Joosten I., Allebes W. The presence of donor-specific human leukocyte antigen antibodies does not preclude successful withdrawal of tacrolimus in stable renal transplant recipients. Transplantation 2007, 84:1092-1096.
31. Higgins R., Hathaway M., Lowe D., Lam F., Kashi H., Tan L.C., et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007, 84:876-884.
32. Bartel G., Regele H., Wahrmann M., Huttary N., Exner M., Hörl W.H., Böhmig G.A. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008, 8:2652-2660.
33. Heinemann F.M., Roth I., Rebmann V., Arnold M.L., Witzke O., Wilde B., et al. Immunoglobulin isotype-specific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol 2007, 68:500-506.
34. Bartel G., Wahrmann M., Exner M., Regele H., Huttary N., Schillinger M., et al. In vitro detection of C4d-fixing HLA alloantibodies: Associations with capillary C4d deposition in kidney allografts. Am J Transplant 2008, 8:41-49.
35. Arnold M.L., Dechant M., Doxiadis S.B.M. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens 2008, 72:60-66.
36. Lobashevsky A., Rosner K., Goggins W., Higgins N. Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transpl Immunol 2010, 23:81-85.
37. Ozawa M., Rebellato L.M., Terasaki P.I., Tong A., Briley K.P., Catrou P., Haisch C.E. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl 2006, 265-290.
38. Duquesnoy R.J., Awadalla Y., Lomago J., Jelinek L., Howe J., Zern D., et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR, DQ, DP epitopes. Transpl Immunol 2008, 18:352-360.
39. McCarron R.M., Wang L., Cowan E.P., Spatz M. ClassMHCII. Antigen expression by cultured human cerebral vascular endothelial cells. Brain Res 1991, 566:325-328.
40. Otsuka A., Hanafusa T., Miyagawa J., Kono N., Tarui S. Nicotinamide and 3-aminobenzamide reduce interferon-gamma-induced class II MHC (HLA-DR and -DP) molecule expression on cultured human endothelial cells and fibroblasts. Immunopharmacol Immunotoxicol 1991, 13:263-280.
41. Haraldsen G., Sollid L.M., Bakke O., Farstad I.N., Kvale D., Molberg, et al. Major histocompatibility complex class II-dependent antigen presentation by human intestinal endothelial cells. Gastroenterology 1998, 114:649-656.
42. Markus B.H., Colson Y.L., Fung J.J., Zeevi A., Duquesnoy R.J. HLA antigen expression on cultured human arterial endothelial cells. Tissue Antigens 1988, 32:241-253.
43. Eberlein-Gonska M., Sill H., Waldherr R. Expression of class I and class II histocompatibility antigens in inflammatory kidney diseases. Verh Dtsch Ges Pathol 1989, 73:117-123.
44. Muczynski K.A., Cotner T., Anderson S.K. Unusual expression of human lymphocyte antigen class II in normal renal microvascular endothelium. Kidney Int 2001, 59:488-497.
45. Deng C.T., El-Awar N., Ozawa M., Cai J., Lachmann N., Terasaki P.I. Human leukocyte antigen class II DQ alpha and beta epitopes identified from sera of kidney allograft recipients. Transplantation 2008, 86:452-459.
46. Morales-Buenrostro L.E., Terasaki P.I., Marino-Vázquez L.A., Lee J.H., El-Awar N., Alberú J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008, 86:1111-1115.
47. Hidalgo L.G., Campbell P.M., Sis B., Einecke G., Mengel M., Chang J., et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009, 9:2532-2541.
48. Lynch R.J., Platt J.L. Accommodation in organ transplantation. Curr Opin Organ Transplant 2008, 13:165-170.
49. Zhang X., Reed E.F. Effect of antibodies on endothelium. Am J Transplant 2009, 9:2459-2465.
50. Iwasaki K., Miwa Y., Haneda M., Uchida K., Nakao A., Kobayashi T. Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun 2010, 391:1210-1215.